Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017
Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander Therapeutics, Inc., the Company's subsidiary.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is a subsidiary of Entest Group Inc. a fully reporting and trades publicly under the symbol: ETNI Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017